FIELD: pharmaceuticals.
SUBSTANCE: disclosed is a stabilized solid preparation having prostaglandin I2 receptor agonist activity, comprising: 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol, having specific surface area in the range from not less than 0.37 to less than 0.7 m2/g. Invention provides stability of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide in the preparation.
EFFECT: disclosed is a pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazine-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide.
22 cl, 7 tbl, 4 ex, 3 dwg
